15th Sep 2025 21:41
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
----------
Investment Co PLC - investment trust focused on UK mid and small-cap companies, managed by Chelverton Asset Management Ltd - Reports results for the year ended June 30. Net asset value per share decreases 0.9% on-year to 79.62 pence at June 30 from 80.30p. NAV total return is minus 0.85% for the year, against plus 17.76% the year before. "The financial period was dominated by the aftermath of the UK election and the headwinds that created for UK quoted small and mid-cap companies," Chair Ian Dighe comments. Looking ahead, he says: "Despite the many headwinds experienced in the UK over the period and the impact this has had on the company's performance we continue to believe that investing in high-quality, quoted, UK small and mid-cap companies will deliver strong capital growth for shareholders over the longer term...As market conditions improve the board and the investment manager look forward to taking advantage of the opportunity presented."
----------
Europa Oil & Gas Holdings PLC - UK and Ireland-focused oil and gas exploration, development and production company - Reports revenue of GBP2.6 million for the 11 months to June 30, down on-year from GBP3.2 million. Pretax loss narrows to GBP1.2 million from GBP6.6 million. Average daily production was 114 barrels of oil equivalent per day, down from 128 boepd "predominantly due to the natural decline of the Wressle-1 well". Average realised oil price decreased to USD73 from USD82. Company says it focused financial activities on "maximising revenues", reducing operating costs on its licences, reducing administrative expenses [to GBP1.3 million from GBP1.7 million], and ending "the unprofitable Whisby 4 net profits agreement". (This relates to a royalty agreement related to the Whisby Field's Whisby-4 well, held with the field's operator BritNRG.) Chief Executive Will Holland says: "The past 11 months have been a period of steady progress and strategic positioning across our portfolio. In Equatorial Guinea, we have advanced our EG-08 licence, launching a farmout process and entering into commercial discussions with a major energy company...In Ireland, our 100%-owned Inishkea West gas prospect continues to attract some interest... In the UK, we have made important strides at Cloughton, submitting the planning application for appraisal drilling and engaging proactively with the local community. Meanwhile, at Wressle, we progressed the development plan and secured financing through a non-dilutive revenue swap agreement." He adds: "With a reshaped board, progressing farmout discussions in Equatorial Guinea, and steady progress in the UK and Ireland, we remain well-positioned to deliver on our strategic objectives in the year ahead."
----------
CRISM Therapeutics Corp - British Virgin Islands-based pharmaceutical firm - Reports results for the six months ended June 30. Company was non-revenue generating during the period, unchanged from the prior year. Continuing pretax loss widened to GBP908,000 from GBP13,000. Administration expenses total GBP905,000, including research and development costs totalling GBP357,000, and up on-year from GBP300,000. CRISM says it is "actively preparing for the commencement of its open-label, registration-grade, phase 2 clinical trial in glioblastoma". Expects patient recruitment in early 2026 with the first patients to be dosed in the first quarter. "The costs of running a clinical trial of this scope are significant and the directors have taken steps to maximise the company's cash runway," CRISM says. "These steps include the negotiation of more favourable terms and payment schedules from key partners and suppliers." "We have also made good progress in our early stage programme in prostate cancer...The initial formulation of docetaxel-ChemoSeed has been developed and the company is seeking non-dilutive grant funding to accelerate development of the programme," says CEO Andrew Webb.
----------
By Emma Curzon, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Investment Co.Europa Oil & GasCrism Thera